Connect with us

Hi, what are you looking for?

Monday, Dec 5, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.

Medical and Pharmaceutical

Delic Labs granted permission to study psychedelics including LSD, MDMA

The Vancouver-based research lab aims to increase understanding of the medical applications of psychedelic compounds

Delic Labs Psychedelics MDMA
Image via Unsplash

Delic Labs, a subsidiary of Delic Holdings Corp. (OTCMKTS: DELCF), (CNSX: DELC), has received a section 56 exemption from Health Canada that will allow scientists to conduct research on a variety of psychedelics including DMT, LSD, MDMA, mescaline and 2C-B.

Based at the University of British Columbia in Vancouver, the federally licensed research lab also received an additional 56 research exemption to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc.

The latest exemptions will assist Delic Labs in developing innovative analytical methods for psychedelic research. The lab aims to establish consistent quality control standards as an increasing number of patients and clinicians incorporate psychedelic compounds into treatment plans.

Read more: Health Canada to increase legal access to psychedelics for therapy

Read more: Numinus set to open Canada’s first psychedelics neurology centre

“Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds,” Dr. Markus Roggen, co-founder of Delic Labs, said in a statement.

Delic Labs received a section 56 research exemption for psilocybin mushrooms in January 2021, allowing the lab to advance extraction methods, analytical testing and chemical process development.

The lab also applied for a dealer’s license last year, aiming to commercialize psilocybin research and associated intellectual property for medical and research purposes. Securing a dealer’s license to accompany its existing research exemptions would position Delic Labs as a leader in psychedelic safety testing.

Read more: Nature amplifies therapeutic effects of psychedelics: study

Read more: Could microdosing psychedelics help treat schizophrenia?

“Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments,” Dr. Roggen said. “We look forward to exploring these novel compounds with the goal of commercializing the research once our dealer’s license is secured.”

Founded by Dr. Roggen and UBC professor Dr. Glenn Sammis, Delic Labs is among a handful of licensed psilocybin research labs in Canada, as well as a leading cannabis analytical and research company.

Delic Holdings Corp. stock closed trading Thursday at $0.062 on the Canadian Securities Exchange.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Ryan Garner on Twitter

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


The government-run pot shop wants to amend limits on THC, introduce stronger QC measures and re-evaluate packaging rules


The bill would reduce 'unreasonably burdensome rules and regulations'


The trial is the first psilocybin study funded by the Canadian Institutes of Health Research (CIHR)


The non-profit trade association received a high level of interest from multiple branches of government